CRISPR Therapeutics LSE:0VRQ Lagerbericht Finanzdaten des Unternehmens + 26 Analysten
CRISPR Therapeutics AG
LSE:0VRQ Lagerbericht
Marktkapitalisierung: US$4.7b
0VRQ Aktienübersicht CRISPR Therapeutics AG, ein Gene Editing Unternehmen, konzentriert sich auf die Entwicklung von genbasierten Medikamenten für schwere menschliche Krankheiten unter Verwendung seiner Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) Plattform.
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen CRISPR Therapeutics AG Wettbewerber Preisentwicklung & Leistung
Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für CRISPR Therapeutics Historische Aktienkurse Aktueller Aktienkurs US$52.28 52-Wochen-Hoch US$91.00 52-Wochen-Tief US$43.47 Beta 1.66 11 Monat Veränderung 11.45% 3 Monate Veränderung 13.26% 1 Jahr Veränderung -4.03% 33 Jahre Veränderung -39.32% 5 Jahre Veränderung -3.20% Veränderung seit IPO 32.53%
Aktuelle Nachrichten und Updates
Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023) Aug 06
Insufficient new directors Jul 01
CRISPR Therapeutics Announces Executive Changes May 24
First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023) May 09
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach May 09
Now 22% undervalued after recent price drop Apr 19 Weitere Updates anzeigen
Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023) Aug 06
Insufficient new directors Jul 01
CRISPR Therapeutics Announces Executive Changes May 24
First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023) May 09
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach May 09
Now 22% undervalued after recent price drop Apr 19
New minor risk - Shareholder dilution Apr 10
CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024 Mar 29
Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022) Feb 22
New minor risk - Shareholder dilution Feb 14 CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia Jan 17
CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024 Dec 20
CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States Dec 09
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease Dec 05
Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022) Nov 07
New minor risk - Share price stability Nov 01
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease Nov 01
CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023 Sep 08
Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022) Aug 08
Now 23% undervalued after recent price drop Aug 08
Insufficient new directors Jul 01
New minor risk - Shareholder dilution Jun 12
Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Jun 10
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Jun 09
First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022) May 09
Now 20% undervalued May 09
Full year 2022 earnings released: US$8.36 loss per share (vs US$4.97 profit in FY 2021) Feb 22
CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023 Dec 20
CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R) Dec 13
Third quarter 2022 earnings released: US$2.24 loss per share (vs US$1.67 loss in 3Q 2021) Nov 02
CRISPR Therapeutics Announces Executive Changes Oct 28
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL) Sep 29
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 Sep 28
Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021) Aug 08
Investor sentiment improved over the past week Jul 06
CRISPR Therapeutics AG Elects Maria Fardis as Board Member Jun 14
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress Jun 13
Investor sentiment improved over the past week Jun 08
Investor sentiment improved over the past week May 18
CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022 May 17
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress May 13
First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021) May 10
Now 22% undervalued after recent price drop May 06
CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors Apr 13
Investor sentiment improved over the past week Mar 11
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 16
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) Feb 03
Investor sentiment deteriorated over the past week Jan 10
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell Malignancies Nov 24
Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020) Nov 05
Second quarter 2021 earnings released: EPS US$10.01 (vs US$1.30 loss in 2Q 2020) Jul 30
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy Jun 11
First quarter 2021 earnings released: US$1.51 loss per share (vs US$1.15 loss in 1Q 2020) Apr 29 Aktionärsrenditen 0VRQ GB Biotechs GB Markt 7D 5.5% -3.6% -0.8% 1Y -4.0% -15.2% 7.9%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 0VRQ übertraf die Branche UK Biotechs , die im vergangenen Jahr eine Rendite von -15.2 erzielte.
Rendite vs. Markt: 0VRQ hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 7.9 erzielte.
Preisvolatilität Is 0VRQ's price volatile compared to industry and market? 0VRQ volatility 0VRQ Average Weekly Movement 5.7% Biotechs Industry Average Movement 8.8% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.0% 10% least volatile stocks in GB Market 2.6%
Stabiler Aktienkurs: 0VRQ hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: 0VRQDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Die CRISPR Therapeutics AG, ein Unternehmen für Gen-Editierung, konzentriert sich auf die Entwicklung von genbasierten Medikamenten für schwerwiegende menschliche Krankheiten unter Verwendung seiner CRISPR-Plattform (Clustered Regularly Interspaced Short Palindromic Repeats)/CRISPR-associated protein 9 (Cas9). Bei CRISPR/Cas9 handelt es sich um eine Gene-Editing-Technologie, die präzise gezielte Veränderungen der genomischen DNA ermöglicht. Das Unternehmen verfügt über ein Portfolio von therapeutischen Programmen in einer Reihe von Krankheitsbereichen, darunter Hämoglobinopathien, Immun-Onkologie und Autoimmunerkrankungen, in vivo und Typ-1-Diabetes.
Mehr anzeigen CRISPR Therapeutics AG's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von CRISPR Therapeutics im Vergleich zum Marktanteil des Unternehmens? 0VRQ grundlegende Statistiken Marktanteil US$4.68b Gewinn(TTM ) -US$239.59m Umsatz(TTM ) US$202.83m
23.1x Kurs-Umsatz-Verhältnis
-19.5x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 0VRQ Gewinn- und Verlustrechnung (TTM ) Einnahmen US$202.83m Kosten der Einnahmen US$463.89m Bruttogewinn -US$261.06m Sonstige Ausgaben -US$21.47m Umsatz -US$239.59m
Zuletzt gemeldete Gewinne
Sep 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -2.81 Bruttomarge -128.71% Nettogewinnspanne -118.13% Schulden/Eigenkapital-Verhältnis 0%
Wie hat sich 0VRQ auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
